Cargando…

Favorable Biochemical Freedom From Recurrence With Stereotactic Body Radiation Therapy for Intermediate and High-Risk Prostate Cancer: A Single Institutional Experience With Long-Term Follow-Up

Purpose/Objective(s): The current study reports long-term overall survival (OS) and biochemical freedom from recurrence (BFFR) after stereotactic body radiation therapy (SBRT) for men with intermediate and high-risk prostate cancer in a single community hospital setting with early adoption. Material...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ricco, Anthony, Barbera, Gabrielle, Lanciano, Rachelle, Feng, Jing, Hanlon, Alexandra, Lozano, Alicia, Good, Michael, Arrigo, Stephen, Lamond, John, Yang, Jun
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2020
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7545336/ https://www.ncbi.nlm.nih.gov/pubmed/33102201 http://dx.doi.org/10.3389/fonc.2020.01505

Ejemplares similares

Repeat Thoracic Stereotactic Body Radiation Therapy (SBRT) for Nonsmall Cell Lung Cancer: Long-Term Outcomes, Toxicity, and Dosimetric Considerations
por: Ricco, Anthony, et al.
Publicado: (2020)

Stereotactic Body Radiation Therapy for Patients with Heavily Pretreated Liver Metastases and Liver Tumors
por: Lanciano, Rachelle, et al.
Publicado: (2012)

The Comparison of Stereotactic Body Radiation Therapy and Intensity-Modulated Radiation Therapy for Prostate Cancer by NCCN Risk Groups
por: Ricco, Anthony, et al.
Publicado: (2016)

Survival and Control Prognosticators of Recurrent Gynecological Malignancies of the Pelvis and Para-aortic Region Treated with Stereotactic Body Radiation Therapy
por: Hasan, Shaakir, et al.
Publicado: (2016)

Propensity Score Matched Comparison of Intensity Modulated Radiation Therapy vs Stereotactic Body Radiation Therapy for Localized Prostate Cancer: A Survival Analysis from the National Cancer Database
por: Ricco, Anthony, et al.
Publicado: (2017)

Stereotactic body radiation therapy for the primary treatment of localized prostate cancer
por: Oliai, Caspian, et al.
Publicado: (2012)

Single Institutional Experience of Stereotactic Radiosurgery Alone for First Brain Metastatic Event and Salvage of Second Brain Metastatic Event in a Community Setting with Review of the Literature
por: Ahmad, Shaharyar, et al.
Publicado: (2017)

Salvage Fractionated Stereotactic Radiotherapy with or without Chemotherapy and Immunotherapy for Recurrent Glioblastoma Multiforme: A Single Institution Experience
por: Hasan, Shaakir, et al.
Publicado: (2015)

SBRT: An Opportunity to Improve Quality of Life for Oligometastatic Prostate Cancer
por: Azzam, Gregory, et al.
Publicado: (2015)

SBRT for the Primary Treatment of Localized Prostate Cancer: The Effect of Gleason Score, Dose and Heterogeneity of Intermediate Risk on Outcome Utilizing 2.2014 NCCN Risk Stratification Guidelines
por: Bernetich, Matthew, et al.
Publicado: (2014)

Definitive Treatment of Early-Stage Non-Small Cell Lung Cancer with Stereotactic Ablative Body Radiotherapy in a Community Cancer Center Setting
por: Heal, Cory, et al.
Publicado: (2015)

Stereotactic body radiotherapy for re-irradiation of lung cancer recurrence with lower biological effective doses
por: Patel, Nisha R., et al.
Publicado: (2014)

Propensity score matched comparison of SBRT versus IMRT for the treatment of localized prostate cancer
por: Oliai, Caspian, et al.
Publicado: (2016)

The effect of whole-brain radiation (WBI) and Karnofsky performance status (KPS) on survival of patients receiving stereotactic radiosurgery (SRS) for second brain metastatic event
por: Brown, D. R., et al.
Publicado: (2016)

Lung metastases treated with stereotactic body radiotherapy: the RSSearch® patient Registry’s experience
por: Ricco, Anthony, et al.
Publicado: (2017)

Stereotactic Body Radiotherapy (SBRT) for liver metastasis – clinical outcomes from the international multi-institutional RSSearch® Patient Registry
por: Mahadevan, Anand, et al.
Publicado: (2018)

Early biochemical outcomes following neoadjuvant/adjuvant relugolix with stereotactic body radiation therapy for intermediate to high risk prostate cancer
por: Gallagher, Lindsey, et al.
Publicado: (2023)

Stereotactic Body Radiation Therapy for Low- to Intermediate-risk Prostate Adenocarcinoma
por: Jeong, Bae-Kwon, et al.
Publicado: (2015)

Hypofractionated stereotactic body radiation therapy as monotherapy for intermediate-risk prostate cancer
por: Ju, Andrew W, et al.
Publicado: (2013)

Pandemics, economic freedom, and institutional trade-offs
por: Geloso, Vincent, et al.
Publicado: (2021)

Low incidence of new biochemical and clinical hypogonadism following hypofractionated stereotactic body radiation therapy (SBRT) monotherapy for low- to intermediate-risk prostate cancer
por: Oermann, Eric K, et al.
Publicado: (2011)

Prostate-specific antigen density predicts favorable pathology and biochemical recurrence in patients with intermediate-risk prostate cancer
por: Kang, Ho Won, et al.
Publicado: (2016)

Relaxed sequence constraints favor mutational freedom in idiosyncratic metazoan mitochondrial tRNAs
por: Kuhle, Bernhard, et al.
Publicado: (2020)

Hypofractionated stereotactic radiation therapy for recurrent glioblastoma: single institutional experience
por: Ciammella, Patrizia, et al.
Publicado: (2013)

Ayurveda GCP Guidelines: Need for freedom from RCT ascendancy in favor of whole system approach
por: Patwardhan, Bhushan
Publicado: (2011)

Six degrees of freedom CBCT‐based positioning for intracranial targets treated with frameless stereotactic radiosurgery
por: Dhabaan, Anees, et al.
Publicado: (2012)

Conformal Radiation Therapy or Stereotactic Body Radiation Therapy: Institutional Experience in the Management of Colorectal Liver Metastases by Radiation Therapy
por: He, Zemin, et al.
Publicado: (2018)

Stereotactic Body Radiation Therapy for Low- and Low-Intermediate-Risk Prostate Cancer: Is there a Dose Effect?
por: Katz, Alan J., et al.
Publicado: (2011)

Radiobiological mechanisms of stereotactic body radiation therapy and stereotactic radiation surgery
por: Kim, Mi-Sook, et al.
Publicado: (2015)

A Multi-Institutional Experience of MR-Guided Liver Stereotactic Body Radiation Therapy
por: Rosenberg, Stephen A., et al.
Publicado: (2018)

Stereotactic ablative radiation therapy for spinal metastases: experience at a single Brazilian institution
por: Marta, Gustavo N., et al.
Publicado: (2021)

Stereotactic Ablative Radiation Therapy in 3 Fractions Induces a Favorable Systemic Immune Cell Profiling in Prostate Cancer Patients
por: Palermo, Belinda, et al.
Publicado: (2023)

Gantry-Mounted Linear Accelerator–Based Stereotactic Body Radiation Therapy for Low- and Intermediate-Risk Prostate Cancer
por: Dang, Audrey T., et al.
Publicado: (2019)

Management of Isolated Local Failures Following Stereotactic Body Radiation Therapy for Low to Intermediate Risk Prostate Cancer
por: Aghdam, Nima, et al.
Publicado: (2020)

Freedom of the will /
por: Edwards, Jonathan, 1703-1758
Publicado: (1969)

Freedom /
por: Franzen, Jonathan

Freedom
Publicado: (1890)

Oligo-recurrence predicts favorable prognosis of brain-only oligometastases in patients with non-small cell lung cancer treated with stereotactic radiosurgery or stereotactic radiotherapy: a multi-institutional study of 61 subjects
por: Niibe, Yuzuru, et al.
Publicado: (2016)

Pulmonary oligometastases treated by stereotactic body radiation therapy (SBRT): a single institution’s experience
por: Chai, Guangjin, et al.
Publicado: (2020)

Whole Brain Radiation Therapy Plus Stereotactic Radiosurgery in the Treatment of Brain Metastases Leading to Improved Survival in Patients With Favorable Prognostic Factors
por: Khan, Muhammad, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_uu5n24d1mmkflciq6i9klunjta